Keryx Biopharmaceuticals Completes Transition of CEO Role to Greg Madison
April 30 2015 - 4:30PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative therapies to market for
patients with renal disease (the "Company" or "Keryx"), today
announced the completion of the previously announced transition of
the CEO role from Ron Bentsur to Greg Madison.
"This is a very exciting time in the evolution of Keryx and I am
honored to be taking the helm of our company at this juncture,"
said Greg Madison, the Chief Executive Officer of Keryx. "Over the
course of 2014, Keryx completed the transition from a
development-stage company to a fully integrated commercial
organization, culminating with the FDA approval and commercial
launch of Auryxia™ (ferric citrate) in the United States. The
entire Keryx organization is thankful to Ron for all that he has
done for our company and we wish him well in his future
endeavors."
As per Mr. Bentsur's employment agreement, Mr. Bentsur will also
be stepping down from the Company's Board of Directors, which will
be reduced to seven members.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston,
is focused on bringing innovative therapies to market for patients
with renal disease. In December 2014, the Company launched its
first FDA-approved product, Auryxia (ferric citrate) for the
treatment of elevated serum phosphorus levels in patients with
chronic kidney disease on dialysis, in the United States. In
January 2014, ferric citrate was approved for the treatment of
patients with all stages of CKD in Japan, where it is being
marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc.
and Torii Pharmaceutical Co. Ltd. For more information about Keryx,
please visit www.keryx.com.
Cautionary Statement
Some of the statements included in this press release,
particularly those regarding the commercialization and subsequent
clinical development of Auryxia, may be forward-looking statements
that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: whether
Auryxia will be successfully launched and marketed in the U.S.;
whether Riona® will be successfully marketed in Japan by our
Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.,
Ltd; the risk that the EMA may not concur with our interpretation
of our Phase 3 study results, supportive data, conduct of the
studies, or any other part of our MAA submission and could
ultimately deny approval of the MAA; the risk that we may not be
successful in the development of Auryxia for the treatment of iron
deficiency anemia in non-dialysis dependent chronic kidney disease
patients; and other risk factors identified from time to time in
our reports filed with the Securities and Exchange Commission. Any
forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release
and prior releases are available at http://www.keryx.com. The
information found on our website is not incorporated by reference
into this press release and is included for reference purposes
only.
CONTACT: KERYX CONTACT:
Amy Sullivan
Vice President, Corporate Development and Public Affairs
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024